Global diabetes market set to grow to $44.7 billion in 2015, fuelled by improved treatments

Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As health care moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change. A new analysis from Frost & Sullivan Global Diabetes Market, finds that the market earned revenues of $27.00 billion in 2008 and estimates this to reach $44.70 billion in 2015.

"Improved therapies and innovative drug delivery techniques are anticipated to revolutionise the global diabetes market by 2015," notes Frost & Sullivan program leader Sylvia Miriyam Findlay. "As health care moves towards preventive medicine, the search for a cure for diabetes looks promising," she says.

The emergence of newer classes of drugs to treat diabetes and their co-morbidities is changing the diabetes market landscape. Long-acting GLP-1 analogs are likely to gain significance and almost match the importance of insulin in the near future. This trend is likely to be beneficial for type-2 diabetics who have not responded to other oral anti-diabetic agents.